AstraZeneca PLC (AZN) stock
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca PLC grew revenue 8.6% to $58.74B over fiscal 2025. Operating income rose 37.4% to $13.74B, moving the operating margin from 18.5% to 23.4%. Free cash flow was $11.77B, up 18.4% from a year earlier. At the latest close the market valued the company at $255.76B, 25.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $255.76B
- P/E ratio
- 25.1
- Price to sales
- 4.35
- Price to book
- 5.09
- Dividend yield
- 1.91%
- Free cash flow yield
- 4.60%
Fundamentals
- Revenue
- $58.74B
- Net income
- $10.23B
- EPS, diluted
- $6.54
- Free cash flow
- $11.77B
- Book value per share
- $32.24
- Diluted shares
- 1.56B
Trading
- Previous close
- $165.41
- Open
- $164.51
- Day's range
- $163.91 – $166.10
- Volume
- 2,322,159
- Average volume (20 days)
- 2,776,406
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | AZN | S&P 500 | Difference | AZN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.3% | +0.6% | −1.9 pts | ||
| 3 months | -2.9% | +3.4% | −6.3 pts | ||
| Year to date | -9.9% | +13.3% | −23.2 pts | ||
| 1 year | -2.2% | +16.6% | −18.8 pts | ||
| 3 years | +34.2% | +86.4% | −52.2 pts | +10.3% | +23.1% |
| 5 years | +50.2% | +81.9% | −31.7 pts | +8.5% | +12.7% |
| 10 years | +249.9% | +318.9% | −69.0 pts | +13.3% | +15.4% |
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AstraZeneca filed with the SEC as exhibits to Form 8-K or 6-K
About AstraZeneca
Pharmaceutical Preparations
AstraZeneca PLC is a biopharmaceutical enterprise engaged in the discovery, development, and commercialization of therapeutic products. The organization organizes its medical pipeline across primary disease segments, notably Oncology, Cardiovascular, Renal and Metabolism (CVRM), Respiratory and Immunology, and Rare Diseases. Its investigative assets include novel molecular entities such as T-cell engagers, antibody-drug conjugates, CAR-T therapies, radioconjugates, and gene therapies. These treatments are formulated to assist healthcare professionals, clinical investigators, and patients suffering from cancer, autoimmune disorders, organ damage, and serious rare conditions.
Company profile, executives and historyAstraZeneca stock: common questions
What is AstraZeneca's stock price?
AZN closed at $163.95 on Oct 19, 2026, down 0.88% on the day.
What is AstraZeneca's market cap?
AstraZeneca was worth $255.76B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is AZN's P/E ratio?
AZN trades at 25.1 times earnings, based on diluted earnings per share of $6.54 over fiscal 2025.
How much revenue does AstraZeneca make?
AstraZeneca reported revenue of $58.74B for fiscal 2025, up 8.6% from a year earlier.
Does AstraZeneca pay a dividend?
Yes. AstraZeneca paid $3.13 per share over the last twelve months, a yield of 1.91% at the latest price, and has raised its annual dividend 2 years in a row.
How has AZN stock performed over the past year?
Including dividends, AZN returned -2.2% over the past year, against +16.6% for the S&P 500.
Who are AstraZeneca's competitors?
Companies most similar to AstraZeneca by business, industry and size include BMY, PFE, GSK, REGN, MRK.
See a number that looks wrong?